The Controversies Surrounding Tocilizumab Administration Following Pathogen-Associated Molecular Pattern (PAMP) Induced by COVID-19

• Main Authors: Shayesteh Gheibi (Author), Farhad Najmeddin (Author), Bita Shahrami (Author), Kourosh Sadeghi (Author), Mojtaba Mojtahedzadeh (Author)
• Format: Book
• Published: Research Center for Rational Use of Drugs (RCRUD), 2020-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.18502/jpc.v8i3.4549; 2322-4630; 2322-4509
• Keywords: Tocilizumab; Betacoronavirus; Coronavirus Infections; COVID-19; Pathogen-Associated Molecular Pattern; Therapeutics. Pharmacology; RM1-950; Pharmacy and materia medica; RS1-441
• Source: Journal of Pharmaceutical Care, Vol 8, Iss 3 (2020)

A new corona virus disease (COVID-19) is affected more than 5 million people worldwide to date and has become a global pandemic. Since there is no definitive cure for this life threatening disease, many clinical studies are underway in this regard. Pathogen-associated molecular patterns (PAMP) prompting by coronavirus seems to generate cellular, structural, and functional derangement induced by immune dysregulation and many biological abnormalities including cytokine storm. The role of IL-6 in viral pneumonia and also the impact of its inhibition on the prevention of organ damage are not known yet.IL-6 seems to behave as a double blade evil cytokine, with a valuable role in cell to cell natural physiological communication. Tocilizumab as an inhibitor of interleukin (IL)-6, may interrupt the paracrine system while causing dissemination of bacterial, fungal, and other viral infections, especially COVID-19, who are at high-risk development of sepsis and life-threatening superinfection.